Q（Question）

When a physician or pharmacist requests information on administration to pediatric patients that is not explicitly described in the package insert, what information may be provided?

A（MHLW answer）

Same as A1.

So what (meaning): The same Q1 conditions apply to pediatric use information absent from the package insert. Providing evidence-based information after internal review is permitted, and negative information must also be disclosed.

So why (rationale): Pediatric off-label use information is in high clinical demand yet often evidence-limited, so the Q1 framework of evidence requirements and mandatory negative-information disclosure is applied equally.

Commentary — background, application, practical notes

Japan's framework for mandating pediatric clinical trials is weaker than that for adults, and many drugs carry package insert language stating only that 'safety and efficacy in pediatric patients have not been established,' without specific dosing guidance. Despite this, pediatric, neonatal, and pediatric oncology settings frequently require that information, and physicians in those fields regularly turn to manufacturers for age-appropriate or weight-based dosing data. Q5 clarifies that the Q1 framework applies equally to pediatric use information absent from the package insert.

A typical request involves a physician asking for foreign pediatric society guidelines or overseas package insert data as the basis for dosing a pediatric patient with an adult-approved drug, or a physician at a center with pediatric prescribing experience asking whether the company holds internal stability or safety data for that population. The former may be provided as third-party evaluated documents under Q1's framework; the latter requires clear disclosure of scientific basis and test conditions.

The most common error is presenting limited case reports on efficacy — in a setting where pediatric evidence is sparse — without explaining the weakness of the dosing rationale or the need for safety monitoring. Adding speculative statements such as 'the safety profile is likely similar to that in adults' is also impermissible. When providing information not present in the package insert, the responsibility to clearly communicate the limits of the evidence rests with the company.